These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 16911843

  • 1. Transcriptional alterations and chromatin remodeling in polyglutamine diseases.
    Helmlinger D, Tora L, Devys D.
    Trends Genet; 2006 Oct; 22(10):562-70. PubMed ID: 16911843
    [Abstract] [Full Text] [Related]

  • 2. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes.
    Helmlinger D, Hardy S, Sasorith S, Klein F, Robert F, Weber C, Miguet L, Potier N, Van-Dorsselaer A, Wurtz JM, Mandel JL, Tora L, Devys D.
    Hum Mol Genet; 2004 Jun 15; 13(12):1257-65. PubMed ID: 15115762
    [Abstract] [Full Text] [Related]

  • 3. Polyglutamine-expanded ataxin-7 upregulates Bax expression by activating p53 in cerebellar and inferior olivary neurons.
    Wang HL, Chou AH, Lin AC, Chen SY, Weng YH, Yeh TH.
    Exp Neurol; 2010 Aug 15; 224(2):486-94. PubMed ID: 20546728
    [Abstract] [Full Text] [Related]

  • 4. Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction.
    Helmlinger D, Hardy S, Abou-Sleymane G, Eberlin A, Bowman AB, Gansmüller A, Picaud S, Zoghbi HY, Trottier Y, Tora L, Devys D.
    PLoS Biol; 2006 Mar 15; 4(3):e67. PubMed ID: 16494529
    [Abstract] [Full Text] [Related]

  • 5. Polyglutamine-expanded ataxin-7 causes cerebellar dysfunction by inducing transcriptional dysregulation.
    Chou AH, Chen CY, Chen SY, Chen WJ, Chen YL, Weng YS, Wang HL.
    Neurochem Int; 2010 Jan 15; 56(2):329-39. PubMed ID: 19909779
    [Abstract] [Full Text] [Related]

  • 6. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration.
    Palhan VB, Chen S, Peng GH, Tjernberg A, Gamper AM, Fan Y, Chait BT, La Spada AR, Roeder RG.
    Proc Natl Acad Sci U S A; 2005 Jun 14; 102(24):8472-7. PubMed ID: 15932940
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The ins and outs of a polyglutamine neurodegenerative disease: spinocerebellar ataxia type 1 (SCA1).
    Orr HT.
    Neurobiol Dis; 2000 Jun 14; 7(3):129-34. PubMed ID: 10860780
    [Abstract] [Full Text] [Related]

  • 9. Both normal and polyglutamine- expanded ataxin-7 are components of TFTC-type GCN5 histone acetyltransferase- containing complexes.
    Helmlinger D, Hardy S, Eberlin A, Devys D, Tora L.
    Biochem Soc Symp; 2006 Jun 14; (73):155-63. PubMed ID: 16626296
    [Abstract] [Full Text] [Related]

  • 10. Spinocerebellar ataxia type 7 associated with pigmentary retinal dystrophy.
    Michalik A, Martin JJ, Van Broeckhoven C.
    Eur J Hum Genet; 2004 Jan 14; 12(1):2-15. PubMed ID: 14571264
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hosting neurotoxicity in polyglutamine disease.
    Liu N, Bonini NM.
    Cell; 2006 Dec 29; 127(7):1299-300. PubMed ID: 17190592
    [Abstract] [Full Text] [Related]

  • 13. Identification of genes that modify ataxin-1-induced neurodegeneration.
    Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, Martinez P, Turiegano E, Benito J, Capovilla M, Skinner PJ, McCall A, Canal I, Orr HT, Zoghbi HY, Botas J.
    Nature; 2000 Nov 02; 408(6808):101-6. PubMed ID: 11081516
    [Abstract] [Full Text] [Related]

  • 14. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.
    Butler R, Bates GP.
    Nat Rev Neurosci; 2006 Oct 02; 7(10):784-96. PubMed ID: 16988654
    [Abstract] [Full Text] [Related]

  • 15. Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7.
    Rüb U, Schöls L, Paulson H, Auburger G, Kermer P, Jen JC, Seidel K, Korf HW, Deller T.
    Prog Neurobiol; 2013 May 02; 104():38-66. PubMed ID: 23438480
    [Abstract] [Full Text] [Related]

  • 16. Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment.
    Mookerjee S, Papanikolaou T, Guyenet SJ, Sampath V, Lin A, Vitelli C, DeGiacomo F, Sopher BL, Chen SF, La Spada AR, Ellerby LM.
    J Neurosci; 2009 Dec 02; 29(48):15134-44. PubMed ID: 19955365
    [Abstract] [Full Text] [Related]

  • 17. Polyglutamine toxicity induces rod photoreceptor division, morphological transformation or death in spinocerebellar ataxia 7 mouse retina.
    Yefimova MG, Messaddeq N, Karam A, Jacquard C, Weber C, Jonet L, Wolfrum U, Jeanny JC, Trottier Y.
    Neurobiol Dis; 2010 Oct 02; 40(1):311-24. PubMed ID: 20600911
    [Abstract] [Full Text] [Related]

  • 18. A role for both wild-type and expanded ataxin-7 in transcriptional regulation.
    Ström AL, Forsgren L, Holmberg M.
    Neurobiol Dis; 2005 Dec 02; 20(3):646-55. PubMed ID: 15936949
    [Abstract] [Full Text] [Related]

  • 19. Polyglutamine and polyalanine expansions in ataxin7 result in different types of aggregation and levels of toxicity.
    Latouche M, Fragner P, Martin E, El Hachimi KH, Zander C, Sittler A, Ruberg M, Brice A, Stevanin G.
    Mol Cell Neurosci; 2006 Mar 02; 31(3):438-45. PubMed ID: 16325416
    [Abstract] [Full Text] [Related]

  • 20. Role of proteolysis in polyglutamine disorders.
    Tarlac V, Storey E.
    J Neurosci Res; 2003 Nov 01; 74(3):406-16. PubMed ID: 14598317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.